• XanaMIA phase 2b/3 Alzheimer's disease trial passes 100th participant milestone
• $13.8m non-dilutive R&D tax incentive funding facility established
• Interim analysis of XanaMIA trial scheduled for January 2026

Actinogen Medical Ltd has released its quarterly activity report and Appendix 4C for the three-month period ended 30 June 2025. Key highlights include the XanaMIA phase 2b/3 Alzheimer's disease (AD) trial passing the 100th participant milestone, with 123 participants enrolled and another 24 having passed the pTau screening. The timeline for a planned safety and efficacy futility interim analysis (IA) by an independent Data Monitoring Committee (DMC) has been established, with the IA scheduled for January 2026 after the enrolment of the 100th participant. The company also announced the establishment of a $13.8m R&D loan facility, with an initial $3.0m tranche secured against the company's FY25 Research and Development Tax Incentive (RDTI). Additional drawdowns of up to $10.8m are conditionally approved against the final FY25 RDTI and the forecast FY26 RDTI. The company continues to progress other key initiatives, including commercial planning, partnering discussions, and intellectual property protection. Actinogen also presented at various international conferences and conducted investment and partnering meetings during the quarter.

The company expects final results for the full enrolment of 220 participants in the XanaMIA trial in Q4 2026. The company also plans to commence an 'open-label' extension trial to allow all participants in the XanaMIA trial to continue with active Xanamem therapy, which is due to start in Q1 2026.